Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this clinical trial is to evaluate the effectiveness and safety of the multifocal Artiflex Presbyopic (Artiplus) intraocular lens.
The study is a prospective, open-label, single-arm, and multicentre clinical investigation with three years of follow-up. Artiflex Presbyopic (Artiplus) is a phakic intraocular lens to be implanted in the anterior chamber, intended for adult subjects and indicated for the optical correction of presbyopia and spherical error requiring a correction.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Artiflex Presbyopic (Artiplus) | Experimental | 49 subjects have received the Artiflex Presbyopic lens (Artiplus) bilaterally and will be followed for 3 years. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Artiflex Presbyopic (Artiplus) implantation | Device | Implantation of iris-fixated multifocal Artiflex Presbyopic IOL (Artiplus) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Improvement in monocular and binocular uncorrected near visual acuity (UNVA) |
| 3 years |
| Improvement in monocular and binocular corrected near visual acuity (CNVA) |
| 3 years |
| Improvement in monocular and binocular distance corrected near visual acuity (DCNVA) |
| 3 years |
| Improvement in monocular and binocular uncorrected intermediate visual acuity (UIVA) |
| 3 years |
| Improvement in monocular and binocular distance corrected intermediate visual acuity (DCIVA) |
| 3 years |
| Improvement in monocular and binocular uncorrected distance visual acuity (UDVA) | Percentage of eyes that achieve UDVA of 0.3 logMAR or better Percentage of eyes that achieve UDVA of 0.0 logMAR or better | 3 years |
| Improvement in monocular and binocular corrected distance visual acuity (CDVA) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Pre-existing pathology or physiology which may be aggravated by the implant or where the implant may interfere with the possibility of examining or treating disease:
Preoperative ocular or systemic condition or medication use that would be expected to present undue risk to the subject, that can predispose for future complications or confound the outcome(s) of the study. E.g. the systemic use of alpha-1a adrenergic receptor antagonists was suggested to increase the occurrence of intraoperative floppy iris syndrome, alter iris morphology - or more specifically reduce iris thickness at the site of potential IOL enclavation - and increase postoperative endothelial cell loss.
Previous ocular surgery which might affect the outcome of the study
Concurrent participation or participation during the last 30 days in another drug or device investigation
Secondary surgical procedure planned during the first 6 months of the study (e.g. laser treatment to correct astigmatism)
Amblyopia
Preoperative anterior chamber depth measurement of below 3.0 mm for subjects < 40 years old and 2.8 mm for subjects > 40 years old. Anterior chamber depth is being measured from corneal endothelium to the anterior pole of the crystalline lens. This will result in a critical distance between PIOL and endothelium of 1.5 mm or more as simulated with anterior segment imaging.
White-to-white smaller than 10.5 mm
Subjects not meeting the age specific minimum preoperative endothelial cell density as defined below:
31 to 35 years of age 2400 cells/mm2; 36 to 45 years of age 2200 cells/mm2; > 45 years of age 2000 cells/mm2
Corneas with high rates of polymegethism (a coefficient of variation over 0.40) and pleomorphism (the presence of less than 50% hexagonal cells).
Abnormal iris (e.g. convex, bulging or volcano shaped iris)
Crystalline lens rise of 600 µm or more
Abnormal cornea (keratoconus, opaque cornea, corneal scars, post corneal transplant, corneal dystrophy, or other)
Ocular surface conditions which might influence the quality of vision and affect the outcome of the study
Abnormal pupil (e.g. nonreactive, fixed)
Ectopic pupil
Pupil in photopic light conditions smaller than 2.6 mm
Pupil in scotopic light conditions greater than 7.0 mm
High preoperative intraocular pressure (>21 mm Hg)
Cataract of any grade
Glaucoma or family history of glaucoma (dependent on the evaluation of physician)
Diabetes or diabetic retinopathy
Acute or chronic inflammation
Chronic or recurrent uveitis or family history of the same condition
Retinal detachments or family history of retinal detachments
Corticosteroid responder
Pregnant or nursing
Unstable refraction (≥ 0.5D of variability in refraction over the last 12 months)
Aged under 18
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| J. Guell, MD | Instituto de MicrocirugÃa Ocular, Barcelona, Spain | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GM st. Mary's Eye clinic | Busan | South Korea | ||||
| Nune Eye Hospital Daegu |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40524363 | Derived | Wanten JC, Cezon J, Nuijts RMMA, Duran de la Colina JA, Royo M, Choe CM, Choi JH, Park CS, Koh IH, Rodriguez DC, Bauer NJC, Guell JL. Six-month performance and safety of an iris-fixated multifocal intraocular lens for presbyopia correction in phakic eyes. J Cataract Refract Surg. 2025 Nov 1;51(11):963-971. doi: 10.1097/j.jcrs.0000000000001722. |
Not provided
Not provided
| ID | Term |
|---|---|
| D011305 | Presbyopia |
| D012030 | Refractive Errors |
| D009216 | Myopia |
| D006956 | Hyperopia |
| ID | Term |
|---|---|
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 3 years |
| Defocus evaluation | Binocular defocus evaluation will be obtained by using the best-corrected distance refraction and then defocusing the image in 0.5 D increments from +1.5 to -5.0 D | 3 years |
| Predictability of the manifest refraction spherical equivalent (MRSE) | The absolute difference between the actually obtained MRSE and the target MRSE | 3 years |
| Predictability of the manifest refraction spherical equivalent (MRSE) | The percentage of eyes that achieves a MRSE of less than or equal to 0.5 D difference between the actual and target MRSE | 3 years |
| Predictability of the manifest refraction spherical equivalent (MRSE) | The percentage of eyes that achieves a MRSE of less than or equal to 1.0 D difference between the actual and target MRSE | 3 years |
| Stability of manifest refraction spherical equivalent (MRSE) | Mean change in MRSE between visits as determined by a paired analysis | 3 years |
| Stability of manifest refraction spherical equivalent (MRSE) | The percentage of eyes that achieves a change in MRSE of less than or equal to 0.5 D between two consecutive refraction measurements | 3 years |
| Stability of manifest refraction spherical equivalent (MRSE) | The percentage of eyes that achieves a change in MRSE of less than or equal to 1.0 D between two consecutive refraction measurements | 3 years |
| Evaluation of visual disturbances using a validated questionnaire | Assessing the percentage of subjects who experience different visual disturbances, by means of questionnaire | 3 years |
| Evaluation of visual disturbances using a validated questionnaire | Assessing the occurrence of the different visual disturbances by means of questionnaire | 3 years |
| Evaluation of visual disturbances using a validated questionnaire | Assessing the severity of the different visual disturbances by means of questionnaire | 3 years |
| Evaluation of visual disturbances using a validated questionnaire | Assessing the bothersomeness of the different visual disturbances by means of questionnaire | 3 years |
| Evaluation of visual disturbances using a validated questionnaire | Assessing the time of onset of visual disturbances by means of questionnaire | 3 years |
| Satisfaction questionnaire |
| 3 years |
| Endothelial cell density | Comparison of the preoperative and postoperative endothelial cell density | 3 years |
| Endothelial cell density | Endothelial cell loss over time | 3 years |
| Endothelial cell density | Additionally, a comparison between the scientific literature reported naturally occurring endothelial cell loss over time (approx. 0.6% per year; Bourne et al., 1997) and the study observed cell loss will be performed | 3 years |
| Adverse event (AEs) / complication rates |
| 3 years |
| Seoul |
| South Korea |
| SU Yonsei Eye Clinic | Seoul | South Korea |
| ICQO | Bilbao | Biscay | Spain |
| IMO | Barcelona | Catalonia | Spain |
| Hospital San Rafael | Madrid | Spain |
| CIMO | Seville | Spain |